mephentermine sulfate

Trade name: wyamine sulfate

Small moleculeapproved

Approved

Dec 29, 1951

Mephentermine, an amphetamine-derived phenethylamine, is an alpha 1 adrenergic receptor agonist and a hypertensive drug. Mephentermine is mainly used as a vasopressor agent with a sympathomimetic action, primarily causing release of noradrenaline and increasing cardiac output due to positive inotropic effect on the myocardium. The injectable preparation of mephentermine is commonly used for the short-term treatment of various hypotensive states such as shock or hypotension accompanying myocardial infarction or spinal anesthesia or surgical procedures like cesarean section. There is evidence on the fetal metabolic effect and placental transfer of mephentermine. However, a few studies have shown that mephentermine is as effective as phenylephrine in preventing maternal hypotension after spinal anesthesia and has similar effect on neonatal outcome. It is being widely used in developing countries like India as it is much more economical than phenylephrine and offers ease of use as it does not necessitate multiple dilutions as injectable. It is also available in India as 10 mg oral tablets. Despite it was thought earlier to have a little stimulant effect its abuse potential has increased, especially in sports due to its stimulant properties. Like amphetamines, it has shown to increase athletic performance in strength exercises and endurance in a dose of 14 mg/70 kg body weight. It has been proposed that phentermine, which is the main metabolite of mephentermine, acts by inhibiting monoaminoxidases A and B. Mephentermine adverse effects has been related to CNS simulation, excessive rises in blood pressure, and arrhythmias. Wyamine Sulfate (brand name of mephentermine sulfate) approved by FDA in 1951 was discontinued in USA. — NCATS

Clinical trial activity

1 trials · 1 clinical orgs · 2 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
0

Earliest trial started Mar 23, 2023 (NCT05706727)

Timeline

1950s

  1. Dec 29, 1951

    American Home Products — Earliest FDA Approval

  2. Dec 29, 1951

    Baxalta — Marketing Organization

  3. Dec 29, 1951

    American Home Products — NDA Organization

  4. Dec 29, 1951

    Baxalta — NDA Secondary Org

2020s

  1. Jan 1, 2023

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

Approval history

  • approvedDec 29, 1951

Chemistry & pharmacology

Loading structure…

SMILES

CNC(C)(C)Cc1ccccc1.CNC(C)(C)Cc1ccccc1.O=S(=O)(O)O
Mol. weight
424.61 g/mol
Lipinski Ro5
Pass
Rule of 3
Yes
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Discontinued

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine
  • mephentermine hemisulfate
  • mephentermine sodium
  • mephentermine sodium
  • mephentermine sulfate
  • mephentermine sulfate
  • mephentermine sulfate
  • mephentermine sulfate
  • mephentermine sulphate
  • mephine
  • n-methylphentermine
  • vialin
  • wyamine
  • wyamine
  • wyamine sulfate
  • wyamine sulfate

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05706727Phase 3Mar 23, 2023KIST Medical College
Showing 1 of 1 trials
Page 1 / 1

Organizations

Research & Development (1)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
KIST Medical CollegeAcademic/Hospital1112023
1 organizations
Page 1 / 1

Marketing (3)

OrganizationOrg typeRelationshipDate
American Home ProductsFor profitNDADec 29, 1951
BaxaltaFor profitMKTGDec 29, 1951
BaxaltaFor profitNDA2Dec 29, 1951